Search results for "Parkinson’s"

showing 10 items of 91 documents

A Diet for Dopaminergic Neurons?

2009

Parkinson's disease (PD) is the second most common neurodegenerative disease, which unfortunately is still fatal. Since the discovery of dopamine (DA) neuronal cell loss within the substantia nigra in PD, the past decades have seen the understanding of the pathophysiological mechanisms underlying the degenerative process advance at a very impressive rate. Nevertheless, there is at present no cure for PD. Although there are no proven therapies for prevention, a large body of evidence from animal studies has highlighted the paramount role of dietary factors in counteracting DA degeneration. Consistently, associations between the risk of developing PD and the intake of nutrients, individual fo…

Dietary recommendations Dopaminergic neurons Neurodegeneration Neuroprotection Parkinson’s disease PreventionSettore BIO/09 - Fisiologia
researchProduct

Amorphous Ropinirole-Loaded Mucoadhesive Buccal Film: A Potential Patient-Friendly Tool to Improve Drug Pharmacokinetic Profile and Effectiveness

2020

Nowadays the therapeutic strategies to manage Parkinson&rsquo

Drugtherapy optimizationparkinson’s diseasemedia_common.quotation_subjectPeppas-Salhin model.Medicine (miscellaneous)orocomucosal filmslcsh:MedicinePeppas-Salhin model02 engineering and technologyPharmacology030226 pharmacology & pharmacyDosage formArticleorocomucosal film03 medical and health sciencesdissolution kinetic0302 clinical medicinebuccal administrationPharmacokineticsOral administrationSettore MED/28 - Malattie OdontostomatologicheMucoadhesionMedicineEudragit® L100media_commonbusiness.industrylcsh:Rex vivo permeationBuccal administration021001 nanoscience & nanotechnologynervous system diseasesropiniroleRopiniroleSettore CHIM/09 - Farmaceutico Tecnologico Applicativo0210 nano-technologybusinessDrug metabolismdissolution kineticsmucoadhesionmedicine.drug
researchProduct

Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)

2002

Abstract The current concept of dyskinesia is that pulsatile stimulation of D-1 or D-2 receptors by l -DOPA or short-acting dopamine agonists is more likely to induce dyskinesia compared to long-acting drugs producing more continuous receptor stimulation. We now investigate the ability of two mixed D-1/D-2 agonists, namely pergolide (long-acting) and apomorphine (short-acting), to induce dyskinesia in drug-naive MPTP-lesioned primates, compared to l -DOPA. Adult common marmosets ( Callithrix jacchus ) were lesioned with MPTP (2 mg/kg/day sc for 5 days) and subsequently treated with equieffective antiparkinsonian doses of l -DOPA, apomorphine, or pergolide for 28 days. l -DOPA, apomorphine, …

Dyskinesia Drug-Inducedmedicine.medical_specialtyParkinson's diseaseL-DOPApergolideMotor ActivityapomorphineSeverity of Illness IndexDopamine agonistAntiparkinson AgentsLevodopaParkinson’s disease.Disability Evaluationchemistry.chemical_compoundParkinsonian DisordersDevelopmental NeuroscienceDopamineInternal medicineAnimalsMedicineMPTPPergolidemarmosetBehavior AnimalReceptors Dopamine D2business.industryReceptors Dopamine D1MPTPCallithrixmedicine.diseasenervous system diseasesApomorphineDisease Models AnimaldyskinesiaEndocrinologyNeurologychemistryDyskinesia1-Methyl-4-phenyl-1236-tetrahydropyridineDopamine receptorDopamine AgonistsSettore BIO/14 - Farmacologiamedicine.symptombusinessmedicine.drugExperimental Neurology
researchProduct

Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1

2014

Abstract Mitochondrial dysfunctions accompany several neurodegenerative disorders and contribute to disease pathogenesis among others in Parkinson’s disease (PD). Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is a major regulator of mitochondrial functions and biogenesis, and was suggested as a therapeutic target in PD. PGC-1α is regulated by both transcriptional and posttranslational events involving also the action of growth factors. Fibroblast growth factor-21 (FGF21) is a regulator of glucose and fatty acid metabolism in the body but little is known about its action in the brain. We show here that FGF21 increased the levels and activity of PGC-1α and elevated mito…

FGF21educationRegulatorNicotinamide phosphoribosyltransferasePGC-1αFGF21; PGC-1α; SIRT1; Dopaminergic neurons; Mitochondria; Parkinson’s diseaseMitochondrionBioinformaticsDopaminergic neuronsSettore BIO/09 - Fisiologia03 medical and health scienceschemistry.chemical_compoundFGF21SIRT10302 clinical medicineDopaminergic Cell030304 developmental biologyDopaminergic neuron0303 health sciencesMultidisciplinarybiologySirtuin 1ResearchDopaminergicMitochondriaCell biologychemistryParkinson’s diseasebiology.protein3111 BiomedicineNAD+ kinase030217 neurology & neurosurgerySpringerPlus
researchProduct

THE ENTERIC NERVOUS SYSTEM: NEW DEVELOPMENTS AND EMERGING CONCEPTS

2011

The enteric nervous system (ENS) is an integrative neuronal network, organized in two ganglionated plexuses, myenteric and submucosal, composed of neurons and enteric glial cells, controlling the activity of the smooth muscle of the gut, mucosal secretion and blood flow. The ENS contains as many neurons as the spinal cord, and the functional and chemical diversity of enteric neurons closely resembles that of the central nervous system. This highly integrated neural system is also referred to as the ‘brain-in-the-gut’, because of its capability to function in the absence of nerve inputs from the central nervous system.

Gastrointestinal system -- Innervation -- Physiologynervous systemGastrointestinal system -- InnervationParkinson’s diseaseParkinson's disease -- TreatmentneurotransmissionEnteric nervous systemEnteric nervous system; neurotransmission; Parkinson’s disease
researchProduct

Effects of a Resistance Training Protocol on Physical Performance, Body Composition, Bone Metabolism, and Systemic Homeostasis in Patients Diagnosed …

2022

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by motor impairments and it is correlated with loss of bone mineral density. This study aimed to analyze the effects of resistance training on bone metabolism, systemic homeostasis, body composition, and physical performance in people with PD. Thirteen subjects (age 64.83 ± 5.70) with PD diagnosis were recruited. Participants performed neuromuscular tests, body composition assessment, and blood sample analysis at baseline, and after an 11 weeks-training period. Each training session lasted 90 min, three times a week. The participants had significant improvements in the timed up and go (p < 0.01), sit to stand (p < …

Health Toxicology and MutagenesisOsteocalcinPublic Health Environmental and Occupational Healthphysical activityResistance TrainingParkinson DiseasePilot ProjectsMiddle AgedPhysical Functional Performanceosteogenesiphysical activity; neurodegenerative disease; resistance training; bone resorption; osteogenesis; osteoporosis; Parkinson’s diseaseneurodegenerative diseaseParkinson’s diseaseBody CompositionHumansHomeostasisosteoporosiCalciumVitamin Dbone resorptionAgedInternational Journal of Environmental Research and Public Health; Volume 19; Issue 20; Pages: 13022
researchProduct

Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy

2020

Recently, the LRP10 gene has been associated with Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The aim of the present study was to evaluate the presence of mutations of the LRP10 gene in patients with PD or DLB from Southern Italy. Sequencing analysis revealed only 2 missense and 3 synonymous variants in patients and control subjects and a rare variant p.L622F in a PD case. These results suggest that LRP10 mutations are not a frequent cause of PD and DLB in Southern Italy.

Lewy Body Diseasemedicine.medical_specialtyNeurologyParkinson's diseaseLRP10 . Parkinson’s disease . Dementia with Lewy bodiesDermatologyDiseasebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineDementia with Lewy bodies; LRP10; Parkinson's disease.mental disordersmedicineDementiaMissense mutationHumans030212 general & internal medicineNeuroradiologyDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesPsychiatry and Mental healthItalyMutationSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgery
researchProduct

Frequency and Correlates of Subjective Memory Complaints in Parkinson’s Disease with and without Mild Cognitive Impairment: Data from the Parkinson’s…

2018

Subjective memory complaints (SMC) may represent the preclinical phase of mild cognitive impairment (MCI) due to Alzheimer's disease. Dementia/MCI have been described with a high prevalence in Parkinson's disease (PD), but whether SMC may predict the development of cognitive impairment has been barely explored. To evaluate the frequency and clinical correlates of isolated SMC (PD-SMC) or within the construct of MCI in subjects with PD, 147 PD patients from the PArkinson's disease COgnitive impairment Study (PACOS) were consecutively recruited for the study. This is a multicenter study involving two Movement Disorder Centers in south Italy. All subjects underwent comprehensive neuropsycholog…

Male0301 basic medicineParkinson's diseaseParkinson's diseaseDiseaseNeuropsychological TestsAnxietyLogistic regressionExecutive Function0302 clinical medicineSurveys and QuestionnairesAttentionCognitive impairmentAged 80 and overGeneral NeuroscienceNeuropsychologyParkinson DiseaseGeneral MedicineMiddle Agedmusculoskeletal systemPsychiatry and Mental healthClinical PsychologyVisual Perceptioncardiovascular systemAnxietySettore MED/26 - NeurologiaFemaleAnxiety; cognitive impairment; disability; motor impairment; Parkinson's disease; subjective complaints; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental Healthmedicine.symptommedicine.medical_specialtyStatistics Nonparametricmotor impairment03 medical and health sciencesInternal medicinemental disordersmedicineHumansDementiaAgedRetrospective Studiescognitive impairmentSubjective complaints Cognitive Impairment Parkinson’s Disease Disability Motor Impairment AnxietyMemory DisordersNeuroscience (all)subjective complaintsbusiness.industrymedicine.diseaseCross-Sectional Studies030104 developmental biologydisabilityEtiologyGeriatrics and GerontologyCognition Disordersbusiness030217 neurology & neurosurgeryJournal of Alzheimer's Disease
researchProduct

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

2010

Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); …

MaleNitric Oxide Synthase Type IIlcsh:ChemistryUbiquitinNeurotoxinlcsh:QH301-705.5Receptor Notch3SpectroscopyNeuronsReceptors NotchbiologyGlial fibrillary acidic proteinMicrofilament ProteinsGeneral MedicineComputer Science ApplicationsCell biologySubstantia NigraNitric oxide synthaseNeuroprotective Agentsmedicine.anatomical_structureBiochemistryNeurogliaNeurogliaMethylhydrazinesneuroimmunological biomarkersTyrosine 3-Monooxygenasesmall moleculeSubstantia nigraParkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small moleculeNeuroprotectionArticleCatalysisInorganic ChemistryGlial Fibrillary Acidic ProteinmedicineAnimalsParkinson Disease SecondaryRats WistarPhysical and Theoretical ChemistryOxidopamineMolecular BiologyTyrosine hydroxylase6-OHDA modelCalcium-Binding ProteinsmildronateOrganic ChemistryCorpus StriatumRatslcsh:Biology (General)lcsh:QD1-999nervous systemParkinson’s diseasebiology.proteinBiomarkersInternational Journal of Molecular Sciences
researchProduct

Preliminary experience with a transcranial magnetic resonance-guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series o…

2018

OBJECTIVETranscranial magnetic resonance–guided focused ultrasound surgery (tcMRgFUS) is one of the emerging noninvasive technologies for the treatment of neurological disorders such as essential tremor (ET), idiopathic asymmetrical tremor-dominant Parkinson’s disease (PD), and neuropathic pain. In this clinical series the authors present the preliminary results achieved with the world’s first tcMRgFUS system integrated with a 1.5-T MRI unit.METHODSThe authors describe the results of tcMRgFUS in a sample of patients with ET and with PD who underwent the procedure during the period from January 2015 to September 2017. A monolateral ventralis intermedius nucleus (VIM) thalamic ablation was pe…

MaleParkinson's diseaseMovement disordershigh-intensity focused ultrasound ablationIntraoperative Neurophysiological Monitoringmedicine.medical_treatmentinterventional030218 nuclear medicine & medical imagingMagnetic resonance guided focused ultrasound surgery0302 clinical medicineThalamusEssential tremorSettore MED/27 - NeurochirurgiaUltrasoundSettore MED/37 - NeuroradiologiaParkinson DiseaseGeneral MedicineMiddle AgedAblationMagnetic Resonance ImagingTreatment OutcomeNeuropathic painBBB = blood-brain barrier; ET = essential tremor; FRFSE = fast recalled FSE; FSE = fast spin echo; FSPGR = fast spoiled gradient echo; FTM = Fahn-Tolosa-Marin; HI-FU = high-intensity focused ultrasound; MRI; MRgFUS; MS = multiple sclerosis; PD = Parkinson’s disease; Parkinson’s disease; QUEST = Quality of Life in Essential Tremor; SWAN = susceptibility-weighted angiography; UPDRS = Unified Parkinson’s Disease Rating Scale; VIM = ventralis intermedius nucleus; brain; essential tremor; high-intensity focused ultrasound ablation; interventional; magnetic resonance–guided focused ultrasound surgery; stereotactic technique; tcMRgFUS = transcranial magnetic resonance–guided focused ultrasound surgerySettore MED/26 - NeurologiaFemaleRadiologymedicine.symptombrain; essential tremor; high-intensity focused ultrasound ablation; interventional; magnetic resonance-guided focused ultrasound surgery; mrgfus; mri; parkinson's disease; stereotactic techniqueMRIAdultmedicine.medical_specialtybrainEssential Tremormagnetic resonance–guided focused ultrasound surgery03 medical and health sciencesmedicineHumansmagnetic resonance-guided focused ultrasound surgeryUltrasonography InterventionalAgedThalamotomybusiness.industryMRgFUSmedicine.diseasestereotactic techniqueparkinson's diseaseParkinson’s diseaseSurgeryNeurology (clinical)businessSettore MED/36 - Diagnostica Per Immagini E Radioterapia030217 neurology & neurosurgeryFollow-Up StudiesNeurosurgical focus
researchProduct